Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 136

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 136
---
 in 2039, not including patent term adjustment or any potential patent term extension.

IPH5301/Anti-CD73

As of December 31, 2024, the principal intellectual property rights related to IPH5301 are solely owned by us, and include one U. S. non-provisional patent application, one European patent application, and other patent applications in certain other countries. If a patent directed to IPH5301 issues from such U. S. patent application, it would have a statutory expiration date in 2040, not including patent term adjustment or any potential patent term extension.

IPH6501

As of December 31, 2024, the principal intellectual property rights related to IPH6501 are solely owned by us, and include one U. S. non-provisional patent application, one European patent application, and other patent applications in certain other countries. If a patent directed to IPH6501 issues from such U. S. patent application, it would have a statutory expiration date in 2042, not including patent term adjustment or any potential patent term extension.

IPH45

As of December 31, 2024, the principal intellectual property rights related to IPH45 are solely owned by us, and include one U. S. non-provisional patent application, one European patent application, and other patent applications in certain other countries. If a patent directed to IPH45 issues from such U. S. patent

application, it would have a statutory expiration date in 2043, not including patent term adjustment or any potential patent term extension.

The term of individual patents depends upon the legal term of patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application or its foreign equivalent in the applicable country. In the United States, a patent’s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. In the United States, a patent may also be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of